Drugs / HJ-004-02
last change Dec 2025 re-read 3 minutes ago

HJ-004-02

Developed for
non-small cell lung carcinoma
Investigated by
Tongji University

Trials 1

2026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07361237 Dec 2025 → Dec 2028 expected non-small cell lung carcinoma Tongji University Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as HJ-004-02 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07361237 ↗
Route Oral “oral administration” NCT07361237 ↗